Therefore, given the analysis of the power to detect GEN1 variants in our discovery sequencing phase by binominal distribution (among 617 Polish HBC families), a large-scale multicenter association study in our genotyping validation phase, which included approximately 16,000 unselected breast cancer cases and 5000 controls from all over Poland, and a genetic homogeneity of the Polish population, we consider that we have sufficient data and power to detect possible associations between GEN1 and breast cancer susceptibility. This evidence concerns the gene GEN1 and breast carcinoma.